Needham & Co Downgrades EPIX Pharmaceuticals (EPIX) to Hold
More News related to EPIX
- Joseph F. Finn, Jr., Assignee for the Benefit of Creditors of EPIX Pharmaceuticals, Inc., Releases Statement Regarding Liquidation Process
- EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient
- Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009
- EPIX Pharma (EPIX) Reports Mixed Q1 Results
- Needham & Co Downgrades EPIX Pharmaceuticals (EPIX) to Hold
More News related to Downgrades
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
Needham & Co downgrades EPIX Pharmaceuticals (Nasdaq: EPIX) from Buy to Hold.
EPIX Pharmaceuticals, Inc. (EPIX) is a biopharmaceutical company focused on discovering, developing and commercializing pharmaceutical products.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
